1 February 2021 in Journal of Thoracic Oncology
The impact of radiotherapy on the heart has become an area of interest in recent years. Many different cardiac dose-volume constraints have been associated with cardiac toxicity and survival; however, no consistent constraint has been found. Many patients undergoing treatment for lung cancer have risk factors for cardiovascular disease or known cardiac comorbidities; however, there is little evidence on the effects of radiotherapy on the heart in these patients. We aim to provide a summary of the existing literature on cardiac toxicity of lung cancer radiotherapy, propose strategies to avoid and manage cardiac toxicity, and suggest avenues for future research.
19 September 2019 in British Journal of Radiology
Lung cancer is the most commonly diagnosed cancer and biggest cause of cancer mortality worldwide with non-small cell lung cancer (NSCLC) accounting for most cases. Radiotherapy (RT) plays a key role in its management and is used at least once in over half of patients in both curative and palliative treatments. This narrative review will demonstrate how the evolution of RT for NSCLC has been underpinned by improvements in RT technology. These improvements have facilitated geometric individualization, increasingly accurate treatment and now offer the ability to deliver truly individualized RT. In this review, we summarize and discuss recent developments in the field of advanced RT in early stage, locally advanced and metastatic NSCLC. We highlight limitations in current approaches and discuss future potential treatment strategies for patients with NSCLC.
1 November 2020 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
For lung cancer patients treated with radiotherapy, dose to the heart is associated with excess mortality. However, it is often not feasible to spare the whole heart. Therefore, our aim is to define cardiac sub-structure(s) and dose thresholds which optimally reduce early mortality. 14 cardiac sub-structures were delineated on 5 template patients with representative anatomies. 1,161 non-small cell lung cancer patients were non-rigidly registered to these 5 template anatomies, mapping their radiotherapy dose. Mean and maximum dose to each sub-structure were extracted and the means evaluated as input to prediction models. The cohort was bootstrapped into two variable reduction techniques: elastic-net LASSO and random forest survival model. Each was optimised to extract variables contributing most to overall survival, model coefficients were evaluated to select these sub-structures. The most important variables, common to both models, were selected and evaluated in multivariable cox-proportional hazard models. A threshold dose was defined and Kaplan-Meier survival curves plotted. 978 patients remained after visual QA of the registration. Ranking the model coefficients across the bootstraps selected the maximum dose to the right atrium, right coronary artery and ascending aorta as the most important factors associated with survival. The maximum dose to the combined cardiac region showed significance in the multivariable model, hazard ratio 1.01Gy-1, p=0.03 after accounting for tumour volume (p<0.001), N-stage (p<0.01) and performance status (p=0.01). The optimal threshold for the maximum dose, equivalent dose in 2Gy fractions, was 23Gy. Kaplan-Meier survival curves showed a significant split, log-rank p=0.008. The max dose to the combined cardiac region encompassing the right atrium, right coronary artery and ascending aorta was found to have the greatest impact on patient survival. A maximum EQD2 dose of 23Gy was identified and should be considered as a dose limit in future studies.
1 August 2020 in Lung Cancer
1 July 2020 in Physics and Imaging in Radiation Oncology
For lung cancer patients treated with radiotherapy, radiation dose to the heart has been associated with overall survival, with volumetric dose statistics widely presented. However, critical cardiac structures are present on the hearts surface, where this approach may be sub-optimal. In this work we present a methodology for creating cardiac surface dose maps and identify regions where excess dose is associated with in worse overall survival. A modified cylindrical coordinate system was implemented to map the cardiac surface dose for lung cancer patients. Validation was performed by mapping the cardiac chambers for 55 patients, fitting a point spread function (PSF) to the blurred edge. To account for this uncertainty, dose maps were blurred by a 2D-Gaussian with width described by the PSF. Permutation testing identified regions where excess dose was associated with worse patient survival. The 99th percentile of the max t-value then defined a cardiac surface region to extract dose, from each patient, to be analysed in a multivariable cox-proportional hazards survival model. Cardiac surface maps were created for 648 lung cancer patients. Cardiac surface dose maps were blurred with a 2D- Gaussian filter of size σφ = 4.3° and σy = 1.3units to account for mapping uncertainties. Permutation testing identified significant differences across the surface of the right atria, p < 0.001, at all timepoints. The median dose to the region defined by the 99th percentile of the maximum t-value was 18.5 Gy. Multivariable analysis showed the dose to this region was significantly associated with survival, hazard ratio 1.01 Gy−1, p = 0.03, controlling for confounding variables. Cardiac surface mapping was successfully implemented and identified a region where excess dose was associated with worse patient survival. This region extended over the right atria, potentially suggesting an interaction with the hearts electrical conduction system.
1 July 2012 in British Journal Of Neurosurgery
Stereotactic radiosurgery (SRS) for brain metastases has been carried out at the Leeds Gamma Knife Centre since March 2009. The aim of this study was to examine the outcomes and toxicity in our initial cohort of patients. The medical records of patients with brain metastases referred to the Leeds Gamma Knife Centre between March 2009 and July 2010 were retrospectively reviewed. Data on survival, primary tumour, Karnofsky performance status, time from diagnosis to identification of brain metastases, previous treatment for brain metastases and results of staging prior to SRS were recorded. Patients were followed up with regular magnetic resonance imaging of the brain for a minimum of 6 months and data on toxicity and oral steroid dose were recorded. Statistical analysis was carried out using SPSS v14.0. Survival curves were compared using the Log Rank test. Fifty eight patients (19 male) had a median survival of 50.4 weeks (95% CI, 32.6–68.2 weeks). Lung (36%) and breast (27%) were the most common primary tumours. Patients with a total volume of metastases treated < 5000 mm3 (p = 0.007) or between 5000 mm3 and 10 000 mm3 (p = 0.01) had significantly improved survival compared with patients with a total treated volume > 10 000 mm3. In addition, largest treated lesion < 5000 mm3 was a positive prognostic factor. Patients with a single metastasis did not survive significantly longer than those with multiple metastases. Steroid dose dropped significantly after SRS (p < 0.01) and was the same or less in 91% of patients. There were only three cases of grade 3 toxicity. Our study reports survival comparable with other series on radiosurgery and demonstrates a significant decrease in steroid dose following treatment. It also shows that the size of the largest treated metastasis and total volume of metastatic disease seemed a better predictor of outcome than number of metastases treated.